New ThromboGenics’ Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston
Leuven, Belgium, 16 August 2017 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that further ocriplasmin clinical and health economic data was presented at the 35th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS). The meeting was held from August 11th through August 15th, 2017 in Boston, MA.
The first poster presentation was ‘Comparison of Visual Results in Patients Receiving Vitrectomy for Macular Hole in One Eye and Ocriplasmin for Vitreomacular Traction in the Fellow Eye’ by Arshad M. Khanani, Greggory Gahn, Victor Gonzalez, Joseph Markoff, Hamzah Khalaf.
Arshad M. Khanani MD, MA, Managing Partner and Director of Clinical Research, Sierra Eye Associates and Clinical Associate Professor, University of Nevada, Reno presented the results from his retrospective analysis designed to determine the difference in best-corrected visual acuity (BCVA) in patients receiving a pars plana vitrectomy (PPV) in the eye with full-thickness macular hole (FTMH) and ocriplasmin for the fellow eye with vitreomacular traction (VMT) but no FTMH.
In his conclusion, Dr Khanani commented: “Patients who underwent PPV for FTMH benefited from early ocriplasmin treatment in their other eye with VMT that had not progressed to FTMH. Administering ocriplasmin to these patients could potentially avoid development of FTMH in the VMT eye thus avoiding a second PPV.”
The second poster presentation, entitled ‘Budget Impact Analysis of Ocriplasmin for the Treatment of Vitreomacular Traction in the United States’ by Peter Kaiser, Tiffany M. Yu, Pravin U. Dugel, Julia A. Haller, Rohit Varma, Renée JG Arnold presented data from the OASIS randomized trial, a 2-year follow-up study evaluating Ocriplasmin for the treatment of symptomatic VMA (VMT) including macular hole.
Peter K. Kaiser, MD, Department of Ophthalmology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, presented a new budget impact model that was developed in accordance with the principles of good practice published by the International Society for Pharmacoeconomics and Outcomes Research.
Dr Kaiser concluded: “The use of ocriplasmin injections for VMT may be affordable to US health plans, as its costs could be offset by an expected reduction in the number of PPVs and a reduction in overall complications. Future research on the cost-effectiveness of ocriplasmin in patients with VMT will be forthcoming to further determine the economic impact of ocriplasmin injections.”